LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022?

Photo by schluditsch from unsplash

the coronavirus transformations are harmless. The Alpha variant had already distinguished itself for the greater speed of contagion compared to the original SARS-CoV-2 virus; the Beta affected younger subjects, between… Click to show full abstract

the coronavirus transformations are harmless. The Alpha variant had already distinguished itself for the greater speed of contagion compared to the original SARS-CoV-2 virus; the Beta affected younger subjects, between 10 and 30 years; Gamma and Epsilon made the already recovered sick again. Lambda has been found to be particularly infectious [5].

Keywords: nasal vaccine; vaccine monoclonal; winning weapon; monoclonal therapy; therapy winning; sars cov

Journal Title: Journal of Global Health
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.